Document is current
Any future updates will be listed below
-
Authors
De Marco, Margot
Basile, Anna
Rosati, Alessandra
Marzullo, Liberato
Turco, Maria Caterina
Ciccarelli, Michele
Vecchione, Carmine
De Laurenzi, Vincenzo
Liu, Yuxi
Paquette, Charlotte
Januzzi, James L. Jr
-
Funding
Funding for this research was provided by:
European Union – Next Generation EU (PNRR-MCNT2-2023-12378342)
University of Salerno (FARB 2021 - Study of the biological activity of extracellular BAG3 protein in the progression of post-infarction myocardial fibrosis)
Adolph Hutter professorship
- License Information
-
More Information
Article History
Received: 13 June 2025
Accepted: 30 September 2025
First Online: 30 October 2025
Competing interests
: M.D.M., A.R., L.M., C.V., V.D.L. and M.C.T. report equity holdings in Fibrosys, an academic spin-off from the University of Salerno. J.L.J. has received research grants from Abbott Diagnostics, Applied Therapeutics, AstraZeneca, HeartFlow, and Novartis; he has received consulting fees/honorarium from Abbott, AstraZeneca, Beckman-Coulter, Boehringer-Ingelheim, Bristol-Myers, Intellia, Jana Care, Novartis, Pfizer, Merck, Roche Diagnostics and Siemens; He participates on data safety monitoring boards or endpoint committees for Abbott, Abbvie, Bayer, CVRx, Pfizer, Roche Diagnostics and Takeda and reports equity holdings in Fibrosys, Imbria Pharmaceuticals and Jana Care. The rest of the authors have nothing to disclose.
